Cell Therapy News/Articles, page-12827

To really see the benefit our cells have, you need to compare the details in the recently published MAGIC biomarker score, and how effective the cells were at treating the sickest of the sick. Score > 0.29.

It is unlikely that other studies have used the MAGIC 0.29 score since it appears to have only recently come out.
The picture isn't just that around 70 - 80% of treated patients survive, it is that the control arm has only 20 - 30% surviving at 12 months.

ibrutinib looks to be 58% effective in the refractory group ( what MSB is targeting ) , where as MSB were 63 - 68%..... and against the worst grades MSB were 70 - 80%....

By the way, it appears they are still completing a phase 1/2 study. Then they will need to do a phase 3